Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

WALTHAM, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. The grants are comprised of $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF). The grants will further the development, characterization and selection of a drug candidate for human clinical trials as well as support the development of tools ("biomarkers") to monitor the desired biological impact of the drugs in clinical trials.

"We are very pleased to receive support from the Muscular Dystrophy Association, the Friedreich's Ataxia Research Foundation and the National Ataxia Foundation, national organizations recognized for their commitment to innovative research aimed at providing new therapeutic options for patients," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. "We believe that establishing partnerships with these non-profit organizations will result in a number of mutual benefits as the program matures and we prepare for human clinical trials."

Friedreich's ataxia is an inherited neurodegenerative disease in which a single gene defect results in inadequate production of the protein frataxin, leading to progressive damage to the nervous system and loss of muscle function. Prior research has demonstrated that production of frataxin protein can be increased in tissue samples and animal models by a family of compounds, suggesting the potential utility of these compounds in slowing or halting disease progression.

In April 2007, Re
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... Emmanuel Labourier, Marianna Goldrick, Ambion, ... that mediate post-transcriptional gene regulation by pairing , ... untranslated region of messenger RNAs and acting , ... and exciting area of research with applications ...
... High Density Oligonucleotide , Microarrays , ... engineered to maximize yields of full-length cDNA , ... 100 ng of input RNA in a single round for GeneChip , ... cRNA synthesis powered by , ...
... , Dmitriy Ovcharenko, Rich Jarvis, ... Ambion, Inc. , , ... is a powerful , experimental ... genes. It is used routinely for gene function analysis, target , ...
Cached Biology Technology:miRNA Expression in White Blood Cells 2miRNA Expression in White Blood Cells 3miRNA Expression in White Blood Cells 4miRNA Expression in White Blood Cells 5Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Delivering siRNAs to Difficult Cell Types 2Delivering siRNAs to Difficult Cell Types 3Delivering siRNAs to Difficult Cell Types 4Delivering siRNAs to Difficult Cell Types 5Delivering siRNAs to Difficult Cell Types 6Delivering siRNAs to Difficult Cell Types 7
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... following highlights summarize research papers that have been recently published ... Journal of Geophysical Research Oceans ( JGR-C ), ... Water Resources Research . In this release: ... , 2. U.S. cities less susceptible to water scarcity than ...
... New and more effective strains of the fungus used to ... scientists unearthed the secret sex life of Sir Alexander Fleming,s ... The scientists from The University of Nottingham, Ruhr-University Bochum, The ... breakthrough in our understanding of the sex life of the ...
... release is available in French and German ... Royal Veterinary College London. Scientists have been able to ... the backbone of early tetrapods, the earliest four-legged animals. High-energy ... to reconstruct the backbones of the 360 million year old ...
Cached Biology News:AGU journal highlights -- Jan. 14, 2013 2AGU journal highlights -- Jan. 14, 2013 3AGU journal highlights -- Jan. 14, 2013 4AGU journal highlights -- Jan. 14, 2013 5AGU journal highlights -- Jan. 14, 2013 6AGU journal highlights -- Jan. 14, 2013 7AGU journal highlights -- Jan. 14, 2013 8AGU journal highlights -- Jan. 14, 2013 9The secret sex life of the penicillin-producing fungus could make it more productive 2Scientists reassemble the backbone of life with a particle accelerator 2Scientists reassemble the backbone of life with a particle accelerator 3
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... V, is used for agitation and mixing applications ... and destaining of gels and blots, and Southern ... rpm) and can handle a maximum load of ... 29 x 21 cm platforms covered with nonsolid ...
... of enzymes involved in matrix degradation. Of ... ten exist in soluble form whereas MT-MMPs ... MT3-MMP also known as MMP14, MMP15, MMP16 ... them to the cell surface. They have ...
... 2,2′-Azino- bis (3-ethylbenzthiazoline-6-sulfonic Acid) ... optimal concentrations of ABTS and H 2 O ... with proprietary stabilizers. Peroxidase substrate that is soluble, ... ELISA. ABTS ™ develops intense blue-green color ...
Biology Products: